ArticleBioinformation2026
FibroScan grading and metabolic correlates of fatty liver disease.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatty liver disease is increasingly recognized as a hepatic manifestation of systemic metabolic dysfunction. This cross-sectional study, conducted among 165 adult patients with ultrasonographic evidence of fatty liver disease, evaluated metabolic risk factors and liver involvement using FibroScan for steatosis grading and liver stiffness measurement. The results revealed a high prevalence of metabolic syndrome, insulin resistance, dysglycemia and atherogenic dyslipidemia among participants, with moderate to severe hepatic steatosis being common. FibroScan grades showed a significant association between higher steatosis levels and worsening metabolic profiles, including body composition, glycemic parameters and insulin resistance. Thus, we show FibroScan as a valuable non-invasive tool for identifying patients at increased metabolic and hepatic risk, allowing for early risk stratification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.